Antifungal Prophylaxis in Liver Transplantation: A Systematic Review and Network Meta‐Analysis
Invasive fungal infections (IFIs) cause significant morbidity and mortality in liver transplant recipients, but the need and best agent for prophylaxis is uncertain. A comprehensive literature search was performed to identify randomized controlled trials comparing regimens for antifungal prophylaxis...
Saved in:
Published in | American journal of transplantation Vol. 14; no. 12; pp. 2765 - 2776 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, NJ
Wiley
01.12.2014
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Invasive fungal infections (IFIs) cause significant morbidity and mortality in liver transplant recipients, but the need and best agent for prophylaxis is uncertain. A comprehensive literature search was performed to identify randomized controlled trials comparing regimens for antifungal prophylaxis in liver transplant recipients. Direct comparisons were made between treatments using random‐effects meta‐analysis and a Bayesian network meta‐analysis was performed for the primary end point of proven IFI. Fourteen studies met inclusion criteria, reporting comparisons of fluconazole, liposomal amphotericin B (L‐AmB), itraconazole, micafungin and placebo. Overall, antifungal prophylaxis reduced the rate of proven IFI (odds ratio [OR] 0.37, confidence interval [CI] 0.19–0.72, p = 0.003), suspected or proven IFI (OR 0.40, CI 0.25–0.66, p = 0.0003) and mortality due to IFI (OR 0.32, CI 0.10–0.83, p = 0.02) when compared to placebo. All‐cause mortality was not significantly affected. There was no difference in risk of adverse events requiring cessation of prophylaxis (OR 1.11, 95% CI 0.48–2.55, p = 0.81). In the network meta‐analysis an equivalent reduction in the rate of IFI was seen with fluconazole (OR 0.21, CI 0.06–0.57) and L‐AmB (OR 0.21, CI 0.05–0.71) compared with placebo. Routine prophylaxis with fluconazole or L‐AmB reduces the incidence of IFI following liver transplantation, and the available evidence suggests that the two are equivalent in efficacy.
This systematic review and network meta‐analysis demonstrates that fluconazole and liposomal amphotericin B are equally effective agents for antifungal prophylaxis in liver transplant recipients, and both are superior to itraconazole or no prophylaxis. |
---|---|
Bibliography: | SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-1 ObjectType-Article-3 ObjectType-Undefined-4 |
ISSN: | 1600-6135 1600-6143 |
DOI: | 10.1111/ajt.12925 |